NCT06609330 Treatment of Chronic Anger and Aggression Following Military-Related Betrayal
| NCT ID | NCT06609330 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Texas Health Science Center at San Antonio |
| Condition | Anger Problems |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-03-17 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-03-17 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if a treatment designed to deal with anger and aggression from a past betrayal will work. The study will be done on active duty military service members and veterans aged 18 or older. The main questions it aims to answer are: * Will participants be satisfied with the treatment, and is the treatment feasible to do in a military outpatient setting * Will the treatment help with anger and aggression issues. Researchers will compare differences in groups that have different wait times (2-, 3-, or 4-weeks). Participants will complete surveys before, during and after the treatment. The treatment will be 14 modules given twice a week. About 1 month after treatment ends, surveys will be taken again.
Eligibility Criteria
Inclusion Criteria: * Adult active duty military service members and veterans aged 18 or older. * Endorses a history of military-related betrayal (on the Modified Moral Injury Questionnaire) * Endorses problematic anger in the past month (as evidenced by a score of 12 or above on the Dimensions of Anger Reactions; DAR-5) * Engaged in at least 1 self-reported act of aggression in the past 1 month (on the Overt Aggression Scale-Modified; OAS-M) Exclusion Criteria: * Participated in an anger management or trauma-focused intervention within the past 3 months as assessed by self-report. * Acute suicidality requiring immediate intervention, such as hospitalization as assessed by the Depressive Symptoms Index-Suicidality Subscale (DSI-SS) combined with follow up clinical interview for elevated scores. * Is currently homicidal with plans and intent to hurt a specific person and requiring immediate intervention as measured by self-report and follow-up with clinician if screened positive. * Moderate to severe brain injury as measured by inability to comprehend the informed consent document or baseline assessments. * Has severe alcohol consumption patterns as evidenced by a score of 19 or above on the Alcohol Use Disorders Identification Test (AUDIT). * Experiencing active psychosis or mania as measured by the Prodromal Questionnaire-Brief Version and the Mood Disorders Questionnaire.
Contact & Investigator
Vanessa Jacoby, PhD
PRINCIPAL INVESTIGATOR
The University of Texas Health Science Center at San Antonio
Frequently Asked Questions
Who can join the NCT06609330 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Anger Problems. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06609330 currently recruiting?
Yes, NCT06609330 is actively recruiting participants. Contact the research team at jacobyv@uthscsa.edu for enrollment information.
Where is the NCT06609330 trial being conducted?
This trial is being conducted at Fort Cavazos, United States.
Who is sponsoring the NCT06609330 clinical trial?
NCT06609330 is sponsored by The University of Texas Health Science Center at San Antonio. The principal investigator is Vanessa Jacoby, PhD at The University of Texas Health Science Center at San Antonio. The trial plans to enroll 40 participants.